Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict PET Image Quality of Three Generations EGFR TKI in Advanced-Stage NSCLC Patients

Introduction: Epidermal growth factor receptor (EGFR) mutated NSCLC is best treated using an EGFR tyrosine kinase inhibitor (TKI). The presence and accessibility of EGFR overexpression and mutation in NSCLC can be determined using radiolabeled EGFR TKI PET/CT. However, recent research has shown a si...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	I. H. Bartelink, E. A. van de Stadt, A. F. Leeuwerik, V. L. J. L. Thijssen, J. R. I. Hupsel, J. F. van den Nieuwendijk, I. Bahce, M. Yaqub, N. H. Hendrikse
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	MDPI AG 2022-06-01
Rangatū:	Pharmaceuticals
Ngā marau:	NSCLC EGFR TKI PBPK modeling PET/CT
Urunga tuihono:	https://www.mdpi.com/1424-8247/15/7/796
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!